Home / PARP / HT PARP in vivo Pharmacodynamic ELISA Kit II

HT PARP in vivo Pharmacodynamic ELISA Kit II

4520-096-K 17 Citations Datasheet / COA / SDS
Newer Version Available: 4520B-096-K
NEW
For the quantitation of PAR in peripheral blood mononuclear cells, tissue culture cells, and tumor lysates from different tissues, organs and xenografts
This product has been discontinuation and replaced by catalog # 4520B-096-K

Discontinued Product

4520-096-K has been discontinued and is replaced by 4520B-096-K.

Measurement of PAR Levels in Jurkat Cells_4520-096-K
1 Image
Product Details
Citations (17)
FAQs
Reviews
Summary Product Datasheets Data Images Background

HT PARP in vivo Pharmacodynamic ELISA Kit II Summary

Monitors in vivo PARP activity within cells based on levels of PAR.

Key Benefits

• Pre-coated 96 well capture antibody plates
• High signal to noise ratio
• Detection sensitivity of 2 pg/mL of PAR
• Broad linear dynamic range to 1,000 pg/mL
• Reduced inter-assay variability
• Validated assay that measures drug action on PARP in both in vivo and in vitro settings
• 96 test size

What is the HT PARP In Vivo Pharmacodynamic ELISA Kit II.

Immobilized PAR monoclonal antibody in the wells of a 96-well plate captures cellular PAR and PAR attached to proteins. Incubation with a polyclonal PAR detecting antibody, followed by addition of a goat anti-rabbit IgG-HRP secondary and a chemiluminescent HRP substrate yields relative light units (RLU) that directly correlates with the amount of cellular PAR.

Product Specifications

  • Quantitation of PAR in peripheral blood mononuclear cells, tissue culture cells, and tumor lysates from different tissues, organs and xenografts.
  • Monitoring the efficacy of PARP inhibitors on PAR formation in vivo.
  • Verifying observations of enhanced cancer cell cytotoxicity arising from PARP inhibitor/anticancer drug combination therapy.
  • Facilitating development of PARP and PARG targeted therapeutics.

Kit Contents

• PAR Standard, 25 pg/µl
• WIL2-NS Cell Lysate Control Standard, Low
• WIL2-NS Cell Lysate Control Standard, Medium
• WIL2-NS Cell Lysate Control Standard, High
• PAR Polyclonal Detecting Antibody
• Goat anti-Rabbit IgG-HRP
• DNase I, 2 Units/µl
• PARP Sample Buffer
• PARP Cell Lysis Reagent
• 100X Magnesium Cation
• PARP Antibody Diluent
• 20% SDS
• Pre-coated white 96-stripwell plate and 5 sealers
• PARP PeroxyGlow A
• PARP PeroxyGlow B

Specifications

Shipping Conditions
The components for this kit may require different storage/shipping temperatures and may arrive in separate packaging. Upon receipt, store products immediately at the temperature recommended on the product labels.
Storage
Store the unopened product at -20 to -70 °C. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Do not use past expiration date.
Species
Multi-species

Limitations

For research use only. Not for diagnositic use.

Product Datasheets

Product Datasheet
COA
SDS

Data Example

Measurement of PAR Levels in Jurkat Cells_4520-096-K View Larger

Measurement of PAR Levels in Jurkat Cells. The HT PARP In Vivo Pharmacodynamic Assay II (Catalog # 4520-096-K) was used to measure poly (ADP-ribose) (PAR) levels in cellular extracts from untreated Jurkat human acute T cell leukemia cells, Jurkat cells treated with PJ34, a potent PARP inhibitor, for 1.5 hours, and in Jurkat cell extracts incubated for 30 minutes with PAR glycohydrolase (PARG), an enzyme that digests PAR.

Citations for HT PARP in vivo Pharmacodynamic ELISA Kit II

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

17 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancer
    Authors: Y Ma, P Chen, JA Drisko, D Khabele, AK Godwin, Q Chen
    Oncol Lett, 2020;19(4):2629-2638.  2020
  2. A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice
    Authors: D Zhang, P Baldwin, AS Leal, S Carapelluc, S Sridhar, KT Liby
    Theranostics, 2019;9(21):6224-6238.  2019
  3. Pharmacology of the ATM inhibitor AZD0156: potentiation of irradiation and olaparib responses pre-clinically
    Authors: LC Riches, AG Trinidad, G Hughes, GN Jones, AM Hughes, AG Thomason, P Gavine, A Cui, S Ling, J Stott, R Clark, S Peel, P Gill, LM Goodwin, A Smith, KG Pike, B Barlaam, M Pass, MJ O'Connor, G Smith, EB Cadogan
    Mol. Cancer Ther., 2019;0(0):.  2019
  4. PARP1 is a versatile factor in the regulation of mRNA stability and decay
    Authors: EA Matveeva, LF Mathbout, YN Fondufe-Mi
    Sci Rep, 2019;9(1):3722.  2019
  5. Coupling of PARP1-mediated chromatin structural changes to transcriptional RNA polymerase II elongation and cotranscriptional splicing
    Authors: EA Matveeva, QMH Al-Tinawi, EC Rouchka, YN Fondufe-Mi
    Epigenetics Chromatin, 2019;12(1):15.  2019
  6. A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models
    Authors: K Sun, K Mikule, Z Wang, G Poon, A Vaidyanath, G Smith, ZY Zhang, J Hanke, S Ramaswamy, J Wang
    Oncotarget, 2018;9(98):37080-37096.  2018
  7. Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.
    Authors: Rodler E, Kurland B, Griffin M, Gralow J, Porter P, Yeh R, Gadi V, Guenthoer J, Beumer J, Korde L, Strychor S, Kiesel B, Linden H, Thompson J, Swisher E, Chai X, Shepherd S, Giranda V, Specht J
    Clin Cancer Res, 2016;22(12):2855-64.  2016
  8. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.
    Authors: Lee J, Hays J, Annunziata C, Noonan A, Minasian L, Zujewski J, Yu M, Gordon N, Ji J, Sissung T, Figg W, Azad N, Wood B, Doroshow J, Kohn E
    J Natl Cancer Inst, 0;106(6):dju089.  0
  9. Epstein-Barr Virus Oncoprotein LMP1 Mediates Epigenetic Changes in Host Gene Expression through PARP1.
    Authors: Martin K, Lupey L, Tempera I
    J Virol, 0;90(19):8520-30.  0
  10. Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo.
    Authors: Janzen D, Paik D, Rosales M, Yep B, Cheng D, Witte O, Kayadibi H, Ryan C, Jung M, Faull K, Memarzadeh S
    Mol Cancer Ther, 0;12(12):2917-28.  0
  11. Implementation of validated pharmacodynamic assays in multiple laboratories: challenges, successes, and limitations.
    Authors: Kinders R, Ferry-Galow K, Wang L, Srivastava A, Ji J, Parchment R
    Clin Cancer Res, 0;20(10):2578-86.  0
  12. Global Transcriptome Analysis Reveals That Poly(ADP-Ribose) Polymerase 1 Regulates Gene Expression through EZH2.
    Authors: Martin K, Cesaroni M, Denny M, Lupey L, Tempera I
    Mol Cell Biol, 0;35(23):3934-44.  0
  13. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
    Authors: Cardnell R, Feng Y, Diao L, Fan Y, Masrorpour F, Wang J, Shen Y, Mills G, Minna J, Heymach J, Byers L
    Clin Cancer Res, 0;19(22):6322-8.  0
  14. Predicting enhanced cell killing through PARP inhibition.
    Authors: Horton J, Wilson S
    Mol Cancer Res, 0;11(1):13-8.  0
  15. Base excision repair defects invoke hypersensitivity to PARP inhibition.
    Authors: Horton J, Stefanick D, Prasad R, Gassman N, Kedar P, Wilson S
    Mol Cancer Res, 0;12(8):1128-39.  0
  16. Requirements to assess feasibility of phase 0 trials during major abdominal surgery: variability of PARP activity.
    Authors: Heitz F, du Bois A, Rochon J, Scheil-Bertram S, Hils R, Fisseler-Eckhoff A, Barinoff J, Kaub C, Harter P
    Clin Cancer Res, 0;18(9):2632-7.  0
  17. Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer.
    Authors: Karginova O, Siegel M, Van Swearingen A, Deal A, Adamo B, Sambade M, Bazyar S, Nikolaishvili-Feinberg N, Bash R, O'Neal S, Sandison K, Parker J, Santos C, Darr D, Zamboni W, Lee Y, Miller C, Anders C
    Mol Cancer Ther, 0;14(4):920-30.  0

FAQs

No product specific FAQs exist for this product, however you may

View all FAQs

Reviews for HT PARP in vivo Pharmacodynamic ELISA Kit II

There are currently no reviews for this product. Be the first to review HT PARP in vivo Pharmacodynamic ELISA Kit II and earn rewards!

Have you used HT PARP in vivo Pharmacodynamic ELISA Kit II?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review